11:50 AM EST - Aeterna Zentaris Inc. : reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog. Data showed that AEZS-108 was well tolerated and demonstrated early evidence of antitumor activity in men with CRPC. Aeterna Zentaris Inc.
shares T.AEZ are trading up $0.05 at $1.84.
